(News Bulletin 247) – Erytech Pharma rose by more than 5% on Thursday on the Paris Stock Exchange after the Lyon commercial court dismissed Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma.
In a press release, Erytech welcomes the interim order issued yesterday by the president of the court, who rejected the request of the investment fund, which sought to obtain the postponement of this vote.
Erytech shareholders will therefore be able to vote on the merger project, as initially planned, that is to say on June 23.
The biopharmaceutical company nevertheless notes that an expert has been appointed to examine the merger parity, with the obligation to submit his report within four months.
Erytech emphasizes that this expertise must be carried out at the expense of Akkadian Partners, which has also been ordered to compensate it for the costs that the company has incurred in the context of the procedure.
Under these conditions, Akkadian – which questions the financial conditions of the operation – invited Erytech to postpone the vote on the merger until the end of the four-month deadline set for the legal expert.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
